Discovery of Novel Acyl Coenzyme A: Cholesterol Acyltransferase Inhibitors: Pharmacophore‐Based Virtual Screening, Synthesis and Pharmacology

Abstract

The present study describes ligand-based pharmacophore modeling of a series of structurally diverse acyl coenzyme A cholesterol acyltransferase inhibitors. Quantitative pharmacophore models were generated using HypoGen module of Discovery Studio 2.1, whereby the best pharmacophore model possessing two hydrophobic, one ring aromatic, and one hydrogen bond acceptor feature for inhibition of acyl coenzyme A cholesterol acyltransferase showed a very good correlation coefficient (r = 0.942) along with satisfactory cost analysis. Hypo1 was also validated by test set and cross-validation methods. Developed models were found to be predictive as indicated by low error values for test set molecules. Virtual screening against Maybridge database using Hypo1 was performed. The two most potent compounds (47 and 48; predicted IC₅₀ = 1 nM) of the retrieved hits were synthesized and biologically evaluated. These compounds showed 86% and 88% inhibition of acyl coenzyme A cholesterol acyltransferase (at 10 μg/mL) with IC₅₀ value of 3.6 and 2.5 nM, respectively. As evident from the close proximity of biological data to the predicted values, it can be concluded that the generated model (Hypo1) is a reliable and useful tool for lead optimization of novel acyl coenzyme A cholesterol acyltransferase inhibitors.

Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore‐based virtual screening, molecular docking and molecular dynamics studies

“…We used Discovery Studio 4.0 (DS) for the pharmacophore model generation and virtual screening followed by molecular docking study. DS is a commercial software package consisting of several modules and widely used for pharmacoinformatics studies . In DS, 3D QSAR pharmacophore generation module was used in which a set of DNA GyrB inhibitors and activity data were taken as input to create potential hypotheses.…”

Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification

“…The DS is commercially available software containing several module packages and widely used in the pharmacoinformatics drug discovery [35][36][37][38]. The 3D QSAR Pharmacophore Generation module enables the use of structure and activity data for a set of potential HIV-protease ligand to create hypotheses.…”

Identification of potential ACAT-2 selective inhibitors using pharmacophore, SVM and SVR from Chinese herbs

“…By analyzing the published ACAT pharmacophore [43,44], we found that subtype selectivity was not considered fully. For instance, the ACAT pharmacophore without selectivity was constructed in Mahesh's paper [43], which had only four features.…”

“…By analyzing the published ACAT pharmacophore [43,44], we found that subtype selectivity was not considered fully. For instance, the ACAT pharmacophore without selectivity was constructed in Mahesh's paper [43], which had only four features. While in this paper, both ACAT-1 and ACAT-2 pharmacophores with selectivity had seven features, which showed more features could improve the specificity and selectivity of pharmacophore [44] had constructed the pharmacophore models of ACAT-1 and ACAT-2 inhibitors, respectively.…”